drugset / Trial / NCT06518564
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Phase 2
Recruiting
25 enrolled
Panagiotis Konstantinopoulos, MD, PhD
EMD Serono · collabThe Applebaum Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to see if the combination of study drugs avelumab and M1774 is effective and safe for participants with endometrial cancer. The names of the study drugs involved in this study are: * Avelumab (a type of human IgG1 antibody) * M1774 (a type of ATR inhibitor)
Timeline
- Start
- 2024-11-14
- Primary completion
- 2027-08-31
- Completion
- 2029-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | Intravenous |
| Subject | Tuvusertib | Small molecule | 30 mg | Oral |
| Subject | Tuvusertib | Small molecule | 50 mg | Oral |